Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 5, 2024

Evolving Commercialization and Distribution Models for PDTs

The panel discusses the challenges of delivering prescription digital therapeutics (PDTs) to patients, challenges caused by PDTs being considered behavioral health benefits, pharmacy benefits, medical benefits, and durable medical equipment benefits.

Episodes in this series

Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"

EP. 1 Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"

EP. 2 Payer Needs and Strategies for Evaluating and Covering PDTs

A panel of 4 experts on PDTs

EP. 3 Payers Review Process and Effective Strategies for PDT Coverage

A panel of 4 experts on PDTs

EP. 4 Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Video 5 - "Dawn of the Age of Adopting PDTs"

EP. 5 Dawn of the Age of Adopting PDTs

Video 6 -"Identifying the Most Impactful Disease Areas and Patient Populations for PDTs"

EP. 6 Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

4 KOLs discuss PDTs

EP. 7 Evolving Commercialization and Distribution Models for PDTs

4 KOLs discuss PDTs

EP. 8 Promoting Appropriate PDT Prescribing Through Provider Education and Support

A panel of 4 experts on PDTs

EP. 9 Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

A panel of 4 experts on PDTs

EP. 10 Optimizing Benefit Design and Implementation for Improved PDT Access

A panel of 4 experts on PDTs

EP. 11 PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Weight loss injections. | Image Credit: ricka_kinamoto - stock.adobe.com

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

ByGiuliana Grossi

June 15th 2026

wooden block for health, medicine, insurance, healthcare concept | Image credit: ภัทรชัย รัตนชัยวงค์ - stock.adobe.com

CKD Stage, Proteinuria Tied to Higher HCRU in IgAN

ByLaura Joszt, MA

June 15th 2026

Lawrence Leiter, MD

Evolocumab Cuts MACE by 29% in High-Risk Diabetes Without Prior MI or Stroke: Lawrence Leiter, MD

ByGiuliana Grossi,Lawrence Leiter, MD

June 15th 2026

Experts featured in this series.

Provider Shortages and Diagnostic Complexity: The Compounding Challenges of Mental Health Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 15th 2026 | Updated: June 15th 2026

The Structural and Scientific Gaps Still Undermining DME Care: Rahul Khurana, MD

ByLaura Joszt, MA,Rahul Khurana, MD

June 15th 2026

Trending on AJMC

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

Type 5 Diabetes: A Long-Ignored Condition Gets Its Moment

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

CMS Proposes Permanent Rules for Medicare Drug Price Negotiation